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Background: Parkinson’s disease (PD) is complex and heterogeneous. The numerous susceptibility loci that have
been identified reaffirm the complexity of PD but do not fully explain it; e.g., it is not known if any given PD
susceptibility gene is associated with all PD or a disease subtype. We also suspect that important disease genes
may have escaped detection because of this heterogeneity. We used presence/absence of family history to
subdivide the cases and performed genome-wide association studies (GWAS) in Sporadic-PD and Familial-PD
separately. The aim was to uncover new genes and gain insight into the genetic architecture of PD.
Results: Employing GWAS on the NeuroGenetics Research Consortium (NGRC) dataset stratified by family history
(1565 Sporadic-PD, 435 Familial-PD, 1986 controls), we identified a novel locus on chromosome 1p21 in Sporadic-PD
(PNGRC = 4×10
-8) and replicated the finding (PReplication = 6×10
-3; PPooled = 4×10
-10) in 1528 Sporadic-PD and 796 controls
from the National Institutes of Neurologic Disease and Stroke (NINDS) Repository. This is the fifth PD locus to be
mapped to the short arm of chromosome 1. It is flanked by S1PR1 and OLFM3 genes, and is 200 kb from a multiple
sclerosis susceptibility gene. The second aim of the study was to extend the stratified GWAS to the well-established
PD genes. SNCA_ rs356220 was associated with both Sporadic-PD (OR = 1.37, P = 1×10-9) and Familial-PD (OR = 1.40,
P = 2×10-5). HLA_rs3129882 was more strongly associated with Sporadic-PD (OR = 1.38, P = 5×10-10) than Familial-PD
(OR = 1.12, P = 0.15). In the MAPT region, virtually every single nucleotide polymorphism (SNP) had a stronger effect-size
and lower P-value in Familial-PD (peak P = 8×10-7) than in Sporadic-PD (peak P = 2×10-5).
Conclusions: We discovered and replicated a new locus for Sporadic-PD which had escaped detection in un-stratified
GWAS. This demonstrates that by stratifying on a key variable the power gained due to diminished heterogeneity can
sometimes outweigh the power lost to reduced sample size. We also detected distinct patterns of disease associations
for previously established PD susceptibility genes, which gives an insight to the genetic architecture of the disease and
could aid in the selection of appropriate study population for future studies.
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PD is heterogeneous. Despite the great strides made re-
cently, we still do not have a clear picture of the genetic
architecture of PD, partly because not all the genes have
been identified, and partly because we do not know if a
given gene is associated with all or a subtype of PD. An* Correspondence: hpayami@wadsworth.org
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reproduction in any medium, provided the orimportant outcome of GWAS will be to use the vast in-
formation content that has been gained [1-7] to define
disease subtypes based on their genetic associations. As
a starting point, we posit that using surrogates for the
underlying heterogeneity may help define the disease
subtypes that each gene is associated with and may also
reveal genes that were previously masked by this hetero-
geneity. Here, we use family history as a surrogate. The
majority of PD (70%-85%) is non-familial (henceforth
Sporadic-PD). The remaining 15%-30% of PD patients
have a positive family history (Familial-PD), but rarely do
their kindreds display a Mendelian inheritance patternral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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genic mutations in SNCA, LRRK2, PARK2, PINK1, DJ1,
ATP13A2 and VPS35 [8-16]. The vast majority of Familial-
PD remains idiopathic. The genetic distinction between
idiopathic Familial-PD and Sporadic-PD, if any exists, is
unknown.
Idiopathic PD involves complex interactions between
the genome and environmental exposures [6,7,17,18]. It
is operationally assumed that the same set of susceptibil-
ity genes predispose to Familial and Sporadic-PD. In
fact, GWAS have successfully uncovered numerous sus-
ceptibility loci without separating the subtypes [1-7]. We
hypothesized that Familial-PD and Sporadic-PD have
different genetic structures. We acknowledge that since
genetic disease can manifest without a family history
due to incomplete penetrance (e.g., LRRK2 mutations
[19]), and environmentally-induced disease can cluster
in families due to common exposure, there must exist
an invisible overlap between Sporadic and Familial-PD.
However, they might differ in the relative burden of in-
completely penetrant Mendelian genes vs. genes that
confer susceptibility to environmental causes. There is
evidence in the literature that supports this notion: con-
sider three well-established PD-associated genes: GBA,
LRRK2, and HLA. GBA mutations are significantly more
common in Familial than in Sporadic-PD [20]. LRRK2
G2019S is also significantly more common in Familial
than in Sporadic-PD [21]. HLA, on the other hand, is
more strongly associated with Sporadic-PD than with
Familial-PD [3]. There are often no overt phenotypic dif-
ferences between these genetic subtypes. Subtle clinical
differences were only detected after the genes were iden-
tified and subtypes were defined genetically. This in itself
underscores the importance of finding the genes.
Here we report the first GWAS stratified by Sporadic
and Familial-PD which identified a previously unknown
PD susceptibility gene in Sporadic-PD. We also present
evidence for distinct patterns of associations for several
well-established PD susceptibility loci with familial and
sporadic subtypes.
Methods
This study was approved by institutional review boards
at the participating institutions: Albany Medical Center,
Emory University, Kaiser Permanente Northwest Division,
New York State Department of Health, Oregon Health &
Sciences University (OHSU) and the Department of
Veterans Affairs VA Puget Sound Health Care System
(VAPSHCS). All study participants gave informed consent.
All patients and most control subjects gave written
signed consent; a portion of control subjects, recruited
at OHSU and VAPSHCS, who wished to remain an-
onymous read the written informed consent and gave
verbal consent as approved by the institutional reviewboards at OHSU and VAPSHCS respectively. All partici-
pants were adults and gave consent on their own behalf.
No parents or guardians were asked to consent for
the subjects. Subjects were from NGRC and included
2000 persons with PD (435 Familial-PD, 1565 Spora
dic-PD) and 1986 controls (Additional file 1). PD was
diagnosed by movement disorder specialists using UK/
NINDS diagnostic criteria [22]. Controls were free of
neurodegenerative disease, 340 of them were examined by
a neurologist. All 3986 subjects were confirmed as genetic-
ally unrelated (PI_HAT ≤ 0.15). Familial-PD was designated
for cases with one or more first or second-degree relatives
with PD; Sporadic-PD was all other cases. There was no
significant difference between Familial and Sporadic cases
in age at recruitment, age at onset, gender, percentage of
Ashkenazi Jews, and the inverse association of smoking
and coffee with PD (Additional file 1).
The genome-wide genotype data were generated by
our group and are publically available on dbGaP (http://
www.ncbi.nlm.nih.gov/gap). Standardized subject selec-
tion criteria, protocols and subject characteristics were
used which are published [3] and are also available on-
line (http://www.ncbi.nlm.nih.gov/gap) with complete
genotype and phenotype data on the entire NGRC cohort
(phs000196.v2.p1). Genome-wide genotyping was per-
formed on DNA from whole blood using the Illumina
HumanOmni1-Quad_v1-0_B array [3]. 811,597 SNPs
passed quality-control (minor-allele frequency ≥0.01, call-
rate ≥99%, Hardy-Weinberg P ≥ 10−6, allele-frequency dif-
ference in men vs. women ≤0.15, missing rate in cases
vs. controls P ≥ 10−5). An additional 6.4 million SNPs
with frequency ≥0.01 were imputed with high fidelity
(info-score ≥90%) using the 1000 Genomes Phase I inte-
grated variant set release v3 and the IMPUTE v.2.2.2
software [23]. The analyses were conducted on the total
of 7.2 million SNPs. For rs2338971 (the top signal on
chromosome 1), the call rate for individuals with imputed
genotype probability ≥90% was 0.98 in cases and 0.98 in
controls. Genotype frequencies in controls for rs2338971
were in Hardy Weinberg equilibrium (P = 0.24).
For replication, we used cases and controls from the
NINDS Human Genetics DNA and Cell Line Repository
(http://ccr.coriell.org/ninds). We obtained the NINDS
GWAS data [2] from dbGaP (http://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id=phs000089.
v3.p2). We used only white non-Hispanic subjects. The
sample size was 924 cases (621 Sporadic-PD, 303 Familial-
PD) and 797 controls. We imputed the two SNPs of in-
terest on chromosomes 1 and 8 with high confidence
(info-score ≥ 0.97). In addition, we had purchased 1490
PD DNA samples (1025 Sporadic, 465 Familial) from the
NINDS Repository. We directly genotyped the DNA sam-
ples using TaqMan. The GWAS dataset and our DNA
samples had only 120 cases in common. This allowed us
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datasets to attain a larger sample size, as well as an oppor-
tunity to validate imputation vs. genotyping results using
the overlapping 120 cases. The genotypes, TaqMan vs. im-
putation, for the top signal at chromosome 1 matched
100% for these 120 individuals. Call rates were 0.95 for ge-
notyped cases, 0.97 for imputed cases with genotype prob-
ability ≥90%, and 0.98 for imputed controls with genotype
probability ≥90%. Controls were in Hardy-Weinberg pro-
portions (P = 0.11). The final sample size for replication
was 2235 cases (1528 Sporadic, 707 Familial) and 796 con-
trols, all from the NINDS Repository.
Statistical analyses for GWAS were performed using
ProbABEL v.0.1-9d [24] adjusting for age at blood draw,
sex and two principal components; and using R version
3.0.1 (http://www.r-project.org/) for replication adjust-
ing for sex and study. Differences in allele frequencies
of Sporadic vs. Familial cases were tested using logistic
regression. Conditional analysis was conducted using
logistic regression. P values shown for replication of
chromosome 1 signal are one-sided, due to the direction-
ality of the hypotheses being tested [25]. Linkage disequi-
librium (LD) was assessed using Haploview V-4.2 [26] and
LocusZoom [27].
We checked the 44 SNPs in the chromosome 1 peak
(those with P < 10-5) for evidence of association with gene
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When GWAS data were analyzed without stratification
(All-PD with 2000 cases, 1986 controls), we recovered
SNCA as the strongest signal; HLA, which also reached
genome-wide significance; and MAPT, which had a clear
peak but fell below the significance threshold (Figure 1A,
Table 1). It is well established that polymorphisms in
SNCA, MAPT, and HLA are associated with PD; it is not
known however if their effects are ubiquitous across all
PD or stronger in Sporadic or Familial subtype.
The top hit for SNCA region was rs356220 at the 3′ of
the gene (All-PD: OR = 1.38, P = 3×10-11). This variant
was also the most significant marker in both Sporadic-
PD (OR= 1.37, P = 1×10-9) and Familial-PD (OR = 1.40,
P = 2×10-5). There was no difference in the SNCA rs356220
allele frequencies in Familial and Sporadic-PD (P = 0.85).
The top hit for HLA was rs3129882 in intron 1 of HLA-
DRA (All-PD: OR = 1.31, P = 3×10-8). This association wasstrong in Sporadic-PD (OR = 1.38, P = 5×10-10) but weak
and statistically non-significant in Familial-PD (OR = 1.12,
P = 0.15). The difference between Sporadic and Familial-
PD in the frequency of HLA-DRA rs3129882 alleles was
significant (P = 6×10-3).
Within the MAPT region, defined from 43.5 Mb to
44.9 Mb on chromosome 17 (Human Genome Build 37)
and including PLEKHM1, MAPT, NSF and WNT3 genes,
2,365 SNPs gave evidence for association with PD
(P < 10-5 in All-PD). The effect sizes for the 2,365 SNPs were
always greater in Familial-PD (0.56 ≤OR ≤ 0.68) than for
Sporadic-PD (0.76 ≤OR ≤ 0.81). Moreover, nearly every SNP
(2,363 of 2,365) achieved higher statistical significance in
Familial-PD (2×10-4 ≥ P ≥ 8×10-7) than in Sporadic-PD
(8×10-4 ≥ P ≥ 2×10-5). The GWAS signal for the MAPT
region peaked at P = 8×10-7 in Familial-PD vs. P = 2×10-5 in
Sporadic-PD. The sample size for Sporadic-PD was 3-times
larger than Familial-PD and therefore power was not a limit-
ing factor in this case because the association was strong in
Familial-PD despite the smaller sample size.
New locus
The GWAS on Sporadic-PD (1565 cases vs. 1986 controls)
revealed two signals, (Figure 1B, Table 1), one on the short
arm of chromosome 1 (a SNP-dense peak with top signal
at rs2338971, P = 4×10-8) and another on chromosome 8
(a single SNP, rs12681349, P = 5×10-8). The GWAS on
Familial-PD (435 cases vs. 1986 controls) did not reveal
any statistically significant signals (Figure 1C).
We tested the new Sporadic-PD signals in an additional
1528 Sporadic-PD cases, 707 Familial-PD cases and 796
controls from the NINDS Repository (Table 1). The signal
on chromosome 1 replicated. In Sporadic-PD, the top
chromosome 1 SNP, rs2338971, gave PReplication = 6×10
-3
with OR = 0.81 which was in the same direction as NGRC
and therefore boosted the significance of the combined
data to PPooled = 4×10
-10. The chromosome 8 signal did
not replicate (Table 1).
The confirmed signal maps to the short arm of
chromosome 1 at p21. The signal is a strong peak with
44 SNPs that achieved 4×10-8 ≤ P < 10-5 for association
with Sporadic-PD in the NGRC dataset. We defined the
new locus based on the location of these 44 SNPs as a
141 kilo base-pair (kb) region from base-pair (bp)
101,872,292 to 102,013,715.
We performed sensitivity analysis testing association of
the top SNP, rs2338971, within subgroups of Sporadic-PD
classified by sex, age at onset, genotype (SNCA, HLA
and MAPT), exposure (smoking, caffeinated-coffee, non-
steroidal anti-inflammatory drugs use), recruitment site,
European countries of ancestral origin, and Ashkenazi
Jewish heritage. Association of rs2338971 with Spora
dic-PD was robust in every stratum with no evidence of
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Figure 1 Genome-wide association P values for All-PD (A), Sporadic-PD (B) and Familial-PD (C). The Manhattan plots (A.1, B.1, C.1) show
the -Log10 P values for association of SNPs with PD within each stratification, plotted according to their location across each chromosome. The
horizontal red line is P = 5×10-8. The quantile-quantile (QQ) plots (A.2, B.2, C.2) depict the distribution of expected P-values for no disease association
(black line) vs. the observed P-values for all SNPs genome-wide (red line), and excluding SNCA (Chr 4 - bp: 90453000 to 91867000), HLA (Chr 6 - bp:
30615000 to 32963000) and MAPT (Chr 17 - bp: 42285000 to 44866000) (blue line).
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namely, PARK6/PINK1, PARK7/DJ1, PARK9/ATP13A2,
and PARK10 (Figure 2A). The new locus is more than 45
mega base-pairs (Mb) away from the closest known PD
locus, which is PARK10. We tested LD between the SNPs
that reached P < 10-5 for association with Sporadic-PD
(44 SNPs) and SNPs that were in or within ±10 kb of DJ1
(66 SNPs), PINK1 (158 SNPs), ATP13A2 (107 SNPs) and
PARK10 (15,796 SNPs). There was no correlation between
the new locus and the known loci (r2 = 0). We therefore
conclude that the signal identified here represents a previ-
ously unknown PD susceptibility locus.
The associated region maps onto a poorly-annotated
gene, huseyo (Figure 2B). Huseyo is transcribed [33,34] but
little is known about the putative protein. rs10493953,which gave OR = 0.64 with P = 1×10-5 for association with
Sporadic-PD is predicted to cause a non-synonymous sub-
stitution (A/G→Q13R) in the putative protein. However,
when we conditioned on the strongest signal (rs2338971),
the signal for the amino-acid changing SNP was lost (P =
10-5 dropped to P = 0.07). The top SNP, rs2338971, also
dropped in significance but was not abolished when con-
ditioned on the amino-acid changing SNP (P = 4×10-8 to
P = 2×10-4). These results suggest neither of these SNPs
can explain the association signal entirely, rather they are
probably tagging an as yet unknown disease-associated
factor in the region.
There are several genes in the region (Figure 2B) includ-
ing VCAM1, SLC30A7, S1PR1 and OLFM3 that could be
considered plausible candidate genes for PD based on







Allele frequency Association with PD
Case Control All-PD Sporadic-PD Familial-PD
All-PD Sporadic Familial OR SE P OR SE P OR SE P
Known highly significant loci
4 SNCA rs356220 90641340 T/C 0.440 0.439 0.443 0.364 1.38 0.07 3×10-11 1.37 0.07 1×10-9 1.40 0.11 2×10-5
6 HLA rs3129882 32409530 G/A 0.459 0.470 0.418 0.395 1.31 0.06 3×10-8 1.38 0.07 5×10-10 1.12 0.09 0.15
17
MAPT
rs199498 44865603 C/T 0.190 0.197 0.162 0.236 0.74 0.05 2×10-6 0.78 0.05 2×10-4 0.59 0.06 8×10-7
New Signals in NGRC
1 rs2338971 101880005 T/C 0.187 0.179 0.213 0.232 0.74 0.04 2×10-7 0.71 0.04 4×10-8 0.86 0.08 0.12
8 rs12681349 4277990 T/C 0.376 0.369 0.403 0.426 0.78 0.04 7×10-7 0.75 0.04 5×10-8 0.88 0.07 0.10
Replication
1 rs2338971 101880005 T/C 0.184 0.182 0.188 0.212 0.82 0.06 5×10-3 0.81 0.07 6×10-3 0.83 0.08 0.03
8 rs12681349 4277990 T/C 0.427 0.420 0.442 0.419 1.02 0.06 0.38 0.99 0.06 0.41 1.09 0.08 0.13
Pooled NGRC and Replication
1 rs2338971 101880005 T/C 0.185 0.181 0.197 0.227 0.76 0.03 5×10-10 0.74 0.04 4×10-10 0.82 0.05 2×10-3
*Genome Build 37.
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possibility that the new signal is tagging a linked gene, we
examined the pattern of LD in the region (Figure 2C).
Using rs2338971 as the anchor we found that strong LD
(r2 ≥ 0.8) extended only 8 kb telomeric and 16 kb centro-
meric; moderate LD (r2 ≥ 0.5) extended 8 kb and 100 kb
and marginal LD (r2 ≥ 0.2) extended 30 kb and 157 kb.
Therefore, even the closest genes to this signal (S1PR1
at ~165 kb telomeric and OLFM3 at ~250 kb centromeric)
were outside the region of marginal LD with it. To be spe-
cific, there was no LD between the 44 SNPs of the new
signal and SNPs in or within ±10 kb of OLFM3 (86 SNPs
tested, r2 = 0) or S1PR1 (11 SNPs tested, 0 ≤ r2 ≤0.08).
The block of SNPs that showed the strongest association
with Sporadic-PD (5×10-8 < P < 5×10-7) overlaps with a
DNA sequence that contains strongly marked regulatory
regions in the ENCODE database [34] (Figure 2D). We
searched five eQTL databases and published expression
data on human brain (see Methods) and did not find evi-
dence for any of the SNPs being an eQTL.
Discussion
Although PD is recognized as a complex and heteroge-
neous disease, it has been treated as a single entity in most
prior GWAS. While GWAS have been enormously suc-
cessful, the discoveries to date are only a fraction of the in-
formation content that these large and expensive datasets
encompass. In this paper, we show that accounting for as-
pects of disease heterogeneity, in this case family history,
could give new insights into the genetic architecture of dis-
ease. Stratifying by family history, we discovered and repli-
cated a new locus for Sporadic-PD which had escaped
detection in un-stratified GWAS. We also detected distinctpatterns of disease associations for some of the previously
established PD susceptibility genes. We did not detect any
new signals for Familial-PD, which is not surprising be-
cause the sample size was small. In order for this approach
to work, the power gained by reducing heterogeneity must
outweigh the power lost to decreased sample size.
This is the fifth PD locus to be mapped to chromo-
some 1p, which including DJ1, ATP13A2, PINK1, and
PARK10, was already coined as a PD hot spot. A mul-
tiple sclerosis (MS) susceptibility locus [35] also maps to
chromosome 1p, only ~200 kb away from the signal for
PD. The gene for MS has not been identified. There are
several plausible candidate genes for PD in the region
(Figure 2). S1PR1 (sphingosine-1-phosphate receptor 1)
encodes a lipid G protein-coupled receptor involved in
cell-cell adhesion, which affects differentiation of endo-
thelial cells and has a crucial role in immune response
[36,37]. VCAM1 (vascular cell adhesion molecule 1) me-
diates leukocyte-endothelial cell adhesion and signal
transduction, and is critical for adult neurogenesis by
maintaining the structure and function of the adult fore-
brain subventricular zone where neuronal stem cells give
rise to neurons [38]. SLC30A7 (solute carrier family
30 member 7) encodes the zinc transporter 7 protein
(ZNT7) [39]. Zinc is required for synaptic neurotransmis-
sion and can also act as an antioxidant [40]. Zinc accumu-
lates selectively in the substantia nigra of PD brains
[41,42], and in rodents, is shown to both enhance and re-
duce excitability of dopaminergic neurons [43]. ENCODE
data [34] show strong markings within the most signifi-
cant region of PD association that are predicted to be
transcription factor binding sites, DNase hypersensitivity
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Figure 2 New region of association with Sporadic-PD. (A) Locations of PD-associated loci on the short arm of chromosome 1. (B) Enlargement
of chromosomal region centered on the new signal and extending 1 Mb in each direction. Red bars are known genes. Hashed red bar, huseyo, is poorly
annotated. Not all known/putative genes in the region are displayed. Blue bars are disease loci that have been mapped but the genes have not been
characterized yet. (C) The LD structure of Sporadic-PD associated SNPs in the 2 Mb region. SNPs within 1 Mb on either side of top SNP, rs2338971, are
plotted, showing –Log10 P values for their association with Sporadic-PD. (D) ENCODE data from UCSC Genome Browser showing evidence of
regulatory sequences.
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compelling evidence for the PD-associated SNPs being
eQTL. The expression data and in-silico methods for com-
bining disease-association and expression data are evolv-
ing rapidly. Studies agree that eQTL patterns vary across
tissues and by cell type [30,45,46]. Thus future studies will
require not only more enriched eQTL datasets (only a
fraction of regulatory elements has been identified) but
also a larger variety of tissues and specific cell types.
Prior GWAS have identified over 20 susceptibility loci
for PD (Additional file 3), of which SNCA, MAPT andHLA have the strongest signals in our data. There is
compelling evidence to suggest that association of PD
with SNCA and HLA involves variations in gene expres-
sion [47-49]. In contrast, there is little information on
the underlying mechanism of the association of PD with
MAPT. Here, we detected distinct patterns in Sporadic and
Familial subtypes. SNCA was associated with All-PD,
MAPT was associated primarily with Familial-PD, and HLA
was associated only with Sporadic-PD. We also explored
differential associations with Familial vs. Sporadic-PD for
all genome-wide significant signals from published studies
Hill-Burns et al. BMC Genomics 2014, 15:118 Page 7 of 9
http://www.biomedcentral.com/1471-2164/15/118(Additional file 3). These distinct patterns can help to
generate new hypotheses and to select subtypes of PD
for specific research questions. The result for SNCA
would suggest an important and central role for this
gene in all forms of PD, which is not a novel thought,
considering that α-synuclein is a major component of
Lewy-bodies and a ubiquitous diagnostic hallmark of
PD. We hypothesize that the stronger association of
MAPT with Familial-PD is indicative of an incom-
pletely penetrant genetic factor, and that pedigrees may
be more informative in studies of MAPT and PD.
Whereas the seemingly exclusive association of HLA
with Sporadic-PD suggests that that risk allele is not a
cause of disease, rather it might be a genetic suscepti-
bility to an environmental agent. Thus, we suggest that
consideration of PD-relevant HLA markers may be par-
ticularly relevant to studies of epidemiology, exposures
and infectious origins of PD.
Conclusions
We discovered and replicated a new locus for Sporadic-
PD which had escaped detection in un-stratified GWAS.
This demonstrates that by stratifying on a key variable
the power gained due to diminished heterogeneity can
sometimes outweigh the power lost to reduced sample
size. We also detected distinct patterns of disease associ-
ations for previously established PD susceptibility genes,
which gives an insight to the genetic architecture of the
disease and could aid in the selection of appropriate
study population for future studies.
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